Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-108459 ascending-dose trial in adults with paroxysmal or persistent atrial fibrillation
NL-OMON41577Active, not recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Atrial fibrillation (AFib) comparing OPC-108459 with Placebo (2 arms). Primary endpoints: Maximum plasma concentration, Area under the concentration-time curve to last measurable concentration and 4 more. Started Jan 2014; status: active, not recruiting.
02
Drugs
OPC-108459
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON41577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41577.